All articles tagged with #phage therapy
Scientists released a high-resolution cryo-EM map of Bas63, a bacteriophage that infects E. coli, revealing how its tail and distinctive surface proteins enable infection and offering a framework to select and optimize phages for treating drug-resistant bacteria; the study also highlights deep evolutionary links between bacteriophages and herpesviruses and builds on prior viral-structure work by the same team.
Researchers comparing E. coli infected with the T7 phage aboard the International Space Station to Earth controls found microgravity altered infection dynamics and drove space-exposed bacteria and phages to accumulate distinct mutations. The ISS-evolved phages developed changes in receptor-binding proteins that improved their ability to infect bacteria, and when tested back on Earth they showed increased activity against common urinary tract infection–causing E. coli strains, suggesting space conditions could inform future phage therapies despite practical costs.
Scientists studied bacteria and their viruses aboard the International Space Station and found that microgravity drives phages to evolve in ways that boost their ability to infect bacteria. When space-adapted phages were returned to Earth, they showed increased activity against common, drug-resistant E. coli strains, suggesting space-driven mutations could help optimize phage therapies for infections on Earth, though the practical costs of space-based research remain a consideration.
A Space.com study compared T7 phage infections of E. coli in identical setups on the ISS and on Earth. In microgravity, infection slowed at short incubation times due to reduced fluid mixing and host stress, but after 23 days the infection could still proceed with fewer bacteria. The research also found microgravity-specific mutations in the phage genome, suggesting space conditions steer phage–host evolution differently. These results have implications for spaceflight microbiology and potentially for Earth-based phage therapies, though more work is needed to assess long-term health risks for astronauts.
A large-scale genomic analysis revealed over 100,000 complete lytic phages embedded within bacterial genomes across diverse species and environments, challenging traditional phage classification and highlighting their potential in therapy and ecology. The study identified new phage lineages, expanded known groups, and found therapeutic phages naturally present in bacterial populations, suggesting a broader and more dynamic phage-bacteria interaction than previously understood.
Researchers are revisiting phage therapy, an old method using viruses to kill bacteria, as a potential solution to the growing problem of antibiotic-resistant superbugs. A recent study highlights how bacteria like Bacillus subtilis defend themselves against phages, revealing new insights that could improve phage therapy's effectiveness. Despite challenges such as immune system interference, the renewed interest aims to develop alternative treatments to antibiotics amid a looming public health crisis.
Researchers designed a hospital-specific phage cocktail, Entelli-02, targeting Enterobacter cloacae complex to combat antimicrobial resistance, demonstrating broad efficacy in vitro, in vivo, and on clinical isolates, with potential for rapid clinical deployment.
The article discusses how understanding bacterial defense systems like Kiwa, a sensor that detects phage attacks, can improve phage therapy to combat antibiotic-resistant infections, highlighting the ongoing microbial arms race and the potential for tailored phage treatments.
A researcher discovers a bacteriophage in toilet water that can kill bacteria causing infections, highlighting the potential of phage therapy as an alternative to antibiotics amid rising antimicrobial resistance. The process involves collecting samples, isolating phages, and testing their ability to target specific bacteria, with promising results for treating infections like urinary tract infections and lung infections. Phage therapy, a century-old concept, is gaining renewed interest due to the growing threat of superbugs and the limitations of antibiotics.
Phage therapy, which uses bacteriophages to target bacterial infections, is gaining renewed interest as an alternative to antibiotics, which are becoming less effective due to overuse and bacterial resistance. Scientists like Biswajit Biswas and Carl Merril are exploring how phages can persist in the body and potentially evolve to avoid being filtered out by the immune system, offering hope against antibiotic-resistant superbugs. This approach, once overshadowed by antibiotics, is being revisited as a promising solution to combat rising bacterial resistance.
A study led by Prof. Ronen Hazan demonstrated the successful use of personalized phage therapy to treat a multidrug-resistant Pseudomonas aeruginosa infection in a Siamese cat named Squeaks. This marks the first documented application of such therapy in veterinary medicine, highlighting its potential to address antibiotic-resistant infections in animals. The treatment involved a combination of a specific anti-P. aeruginosa phage and ceftazidime, leading to the complete healing of the cat's surgical wound after fourteen weeks.
Phage therapy, which uses bacteriophages to target and kill drug-resistant bacteria, is gaining renewed interest as a potential solution to antibiotic resistance. While promising, challenges such as building comprehensive phage libraries, conducting clinical trials for FDA approval, and addressing purification and delivery issues remain. Despite some successful cases, including the treatment of a patient with recurrent blood infections, there are varied outcomes and uncertainties surrounding phage therapy's effectiveness. Researchers and biotech companies are working to overcome these hurdles and bring phage therapy into mainstream medicine as a viable alternative to antibiotics.
A woman with a persistent bacterial infection was successfully treated with an experimental phage therapy, using viruses found in wastewater to target the specific bacteria in her bloodstream. While the treatment initially cleared her infection, the bacteria eventually evolved to resist the phage, and the therapy triggered an immune reaction in the patient. This case highlights both the potential and limitations of phage therapy in combating drug-resistant bacterial infections, with ongoing clinical trials aiming to optimize its effectiveness.
Cynthia Horton, a lupus patient, suffered from antibiotic-resistant ear infections, leading doctors to treat her with phages, tiny viruses that attack bacteria. Phage therapy is being explored as a potential solution to the growing superbug crisis, with clinical trials underway to test its effectiveness against various infections. Scientists are also investigating genetic engineering to target unique antibiotic-resistant pathogens and mass-produce phages. The CDC is interested in using phages to combat superbug recolonization in patients, potentially decreasing the likelihood of infection and transmission to others.
Scientists at the Okinawa Institute of Science and Technology have revealed the molecular structure of the tequintavirus, a type of bacteriophage that infects bacteria. Using cryo-electron microscopy, they obtained atomic models for all structural components of the virus, providing a detailed understanding of its organization at the atomic level. This research has implications for phage therapy, gene therapy, and the engineering of bacteriophages for specific purposes. The study also developed new methods for visualizing complex viruses, which could be applied to other viruses with similar shapes.